Dianthus Therapeutics (DNTH) vs Edgewise Therapeutics (EWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Dianthus Therapeutics (DNTH) over the past year, gaining 161.4% versus a gain of 144.6%. Over five years, EWTX leads with a +123.1% price change compared with -21.2% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $4.30 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | EWTX |
|---|---|---|
| Share price | $84.88 | $39.57 |
| Market cap | $4.75B | $4.30B |
| 1-day change | -0.61% | -1.12% |
| YTD return | +105.97% | +59.46% |
| 1-year return | +144.61% | +161.36% |
| 5-year return | -21.17% | +123.06% |
| EPS (TTM) | $-4.24 | $-1.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | $-167.79M |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $48.51 |
| 52-week low | $32.22 | $14.25 |
| Distance from 52-week high | -27.99% | -18.43% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +65.88% | +32.98% |
| Average volume | 825.33K | 1.35M |
| Shares outstanding | 55.93M | 108.60M |
| Employees | 92 | 127 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed DNTH by 16.7 percentage points over the past year.
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
DNTH vs EWTX FAQ
Which is bigger, Dianthus Therapeutics or Edgewise Therapeutics?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $4.30B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, DNTH or EWTX?
EWTX returned +161.36% over the past 12 months, compared with +144.61% for DNTH (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Edgewise Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.